Probe Capital
探针资本
Probe Capital (探针资本) is a financial advisory firm that serves as exclusive financial advisor on funding rounds for healthcare and technology companies. The bundle shows it in this role for Jianhai Technology (健海科技), an AI-powered disease management platform: it advised on the company's RMB 60 million Series A3 round in 2020 led by Source Code Capital , and again on its RMB 500 million Series B+ round in 2021 where Source Code continued to increase its stake . elsewhere's corpus does not otherwise cover Probe Capital's founding, team, or broader scope of business.
AI-generated — may contain errors, please verify.
Coverage
Source Code Capital portfolio company Jianhai Technology announced the completion of a 500 million RMB Series B+ funding round, with existing shareholder Source Code Capital continuing to increase its stake.
The "Baike Thousand Courtyards" initiative is about to launch.
Source Code Capital portfolio company Jianhai Technology announced the completion of a 150 million yuan Series B investment, with existing shareholder Source Code Capital continuing to increase its stake.
Dedicated to advancing post-diagnosis disease management systems for patients, it has already partnered with more than 1,000 hospitals.
AI-powered disease management platform "Jianhai Technology" announces completion of RMB 60 million Series A3 funding round, led by Source Code Capital
It covers over 400 hospitals at or above the second-tier grade, and is exploring the use of AI for disease management and treatment.
Bluepha Closes RMB 40 Million Series A Round | FreeS Fund Deal Brief
Leading Global Engineered Microbe Development
